RSS
metastatic colorectal cancer (mCRC)
CE-marked liquid biopsy tests launched by Biocartis
Two CE-marked IVD liquid biopsy tests have been launched by molecular diagnostics company, Biocartis Group. — the Idylla ctKRAS Mutation Test and the Idylla ctNRAS-BRAF Mutation Test. Read more
Merck, Pierre Fabre and Array BioPharma collaborate for cancer drug clinical trial
Merck, Array BioPharma and Pierre Fabre have initiated a prospective, randomised, global phase three clinical trial for a treatment of BRAF-mutant metastatic colorectal cancer (mCRC) Read more
Collaboration to develop liquid biopsy RAS biomarker test for cancer
Biocartis has signed a collaboration agreement with Merck for the development and commercialisation of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC) Read more
